Abstract
In the decade following their initial discovery, the suppressor of cytokine signaling (SOCS) proteins have been studied for their potential use as immunomodulators in disease. SOCS proteins, especially SOCS1 and SOCS3, are expressed by immune cells and cells of the central nervous system (CNS) and have the potential to impact immune processes within the CNS, including inflammatory cytokine and chemokine production, activation of microglia, macrophages and astrocytes, immune cell infiltration and autoimmunity. We describe CNS-relevant in vitro and in vivo studies that have examined the function of SOCS1 or SOCS3 under various neuroinflammatory or neuropathological conditions, including exposure of CNS cells to inflammatory cytokines or bacterial infection, demyelinating insults, stroke, spinal cord injury, multiple sclerosis and glioblastoma multiforme.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 392-400 |
| Number of pages | 9 |
| Journal | Trends in Immunology |
| Volume | 30 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2009 |
| Externally published | Yes |
Funding
We thank members of the Benveniste laboratory for helpful discussions on SOCS proteins. This work was funded in part by grants from the National Institutes of Health (NS-57563, NS-50665) and the National Multiple Sclerosis Society (RG 3892-A-12). B.J.B. is supported by NIH T32-NS-48039 and L.N.A. is supported by the UAB Medical Scientist Training Program, by NIH T32-AI-07493 and by NIH F30-NS-65600.
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology